NASH Disease Market Examined in New Topical MP Advisors Report Now Available at MarketPublishers.com
10 Dec 2015 • by Natalie Aster
LONDON – Non-alcoholic fatty liver disease (NAFLD) and its progressive form – non-alcoholic steatohepatitis (NASH) are the most rapidly growing liver diseases in the USA and Europe. NASH is estimated to affect 2 to 5% of the population of the USA. Europe and Japan also have a similar or higher incidence rate for NASH disease. Owing to the varying metabolism and physical traits in different geographies, the development of drug products for NASH is currently facing difficulty. In Japan, for instance, the prevalence of NASH is on the rise although the country’s population is not commonly overweight. Countries such as China and India with a bigger population pool and lifestyles changes face a far greater risk of the disease alongside other lifestyle disorders like diabetes as well as complexities associated with cardiovascular diseases.
There has been growing interest in firms developing drugs for the treatment of NASH. In January 2015, Gilead Sciences acquired Phenex Pharma’s Farnesoid X Receptor (FXR) programme consisting of small molecule FXR agonists to treat liver diseases encompassing NASH and others. Merck-NGM Biopharma and Boehringer Ingelheim - Pharmaxis also initiated an exclusive agreement for the pipeline products which are being developed for NASH with a prospective deal value of close to USD 450-600 million
New research report “Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies” drawn up by MP Advisors provides a detailed analysis on NASH disease and drugs in development in the overall pharmaceutical market. The research publication presents detailed information on the etiology, pathogenesis, diagnosis and present-day treatment of the disease. It offers a comprehensive listing of all the drugs undergoing clinical trials and their design and the population recruited, alongside discussing the pathways representing likely targets for NASH treatment. The report gives an analysis of the drivers of M&A and/or licensing deals in NASH; sheds light on top companies developing drug products to treat NASH; gives a detailed review of the repurposed drugs for NASH. The study keeps track of the opportunities in the NASH disease market up to 2025.
Non-Alcoholic SteatoHepatitis (NASH): An Analysis of Disease Prevalence, Drugs in development, Regulatory guidelines and Market opportunity in Various Geographies
Published: December, 2015
Price: US$ 3,500.00
More comprehensive studies by the publisher can be found at MP Advisors page.